Mason Archival Repository Service

Novel Antimicrobial Development by Targeting the First Two Committed Enzymes in the Methyl Erythritol Phosphate Pathway, DXP Reductoisomerase and MEP Cytidylyltransferase

Show simple item record

dc.contributor.advisor Couch, Robin D
dc.contributor.author Haymond, Amanda Nicole
dc.creator Haymond, Amanda Nicole
dc.date.accessioned 2018-10-22T01:19:48Z
dc.date.available 2018-10-22T01:19:48Z
dc.date.issued 2017
dc.identifier.uri https://hdl.handle.net/1920/11249
dc.description.abstract The threat of both natural and engineered acquisition of antibiotic resistance by microbes necessitates development of novel antimicrobial compounds. The methyl erythritol phosphate (MEP) pathway presents a unique opportunity for such development, as it is both essential in bacteria in which it is found, as well as absent in mammalian cells. The MEP pathway produces two five-carbon lipid precursors isopentenyl pyrophosphate (IPP) and dimethylallyl pyrophosphate (DMAPP), essential cellular building blocks that condense to produce a host of vital downstream isoprenoids. The first two committed enzymes in the pathway, DXP reductoisomerase (IspC) and MEP cytidylyltransferase (IspD), are both promising targets for antimicrobial development. Herein we describe three approaches to identifying and developing novel inhibitors (rational, structure-based drug design; high-throughput screening of a commercial compound library; and high-throughput screening of a natural product library) conducted with both IspC and IspD in order to explore the chemical space for inhibition of these enzymes. To aid in screening a large commercially purchased compound library, we also describe the validation of a high-throughput screening protocol with respect to both IspC and IspD, with appropriate control assays to identify false positive compounds. Based on these library screens, we report promising lead compounds with respect to both enzymes, and propose models for their mechanism of action.
dc.format.extent 324 pages
dc.language.iso en
dc.rights Copyright 2017 Amanda Nicole Haymond
dc.subject Biochemistry en_US
dc.subject antibiotics en_US
dc.subject antimicrobial development en_US
dc.subject antimicrobial resistance en_US
dc.subject enzymology en_US
dc.subject MEP pathway en_US
dc.title Novel Antimicrobial Development by Targeting the First Two Committed Enzymes in the Methyl Erythritol Phosphate Pathway, DXP Reductoisomerase and MEP Cytidylyltransferase
dc.type Dissertation
thesis.degree.level Ph.D.
thesis.degree.discipline Chemistry and Biochemistry
thesis.degree.grantor George Mason University


Files in this item

This item appears in the following Collection(s)

Show simple item record

Search MARS


Advanced Search

Browse

My Account

Statistics